. 2011 Oct 18;6:2367–2374. doi: 10.2147/IJN.S24919

Table 2.

Pharmacokinetic parameters of PZQ-HCO-SLN and PZQ suspension after subcutaneous administration in dog (mean ± SD, n = 5)

Formulation	t_½(ab), hours	t_½(d), hours	t_½(el), hours	t_max, hours	C_max, ng/mL	MRT, hours	AUC_0–∞, ng ·h/mL
PZQ-SLN	0.31 ± 0.11	4.36 ± 1.81	189.62 ± 80.72^a	1.93 ± 1.09	113.70 ± 37.27^a	280.38 ± 116.41^a	5898.17 ± 2048.73^a
Native PZQ	0.97 ± 0.80	2.60 ± 0.79	34.53 ± 19.15	1.45 ± 1.07	47.82 ± 13.06	56.71 ± 23.41	1039.98 ± 149.19

Note: Statistical significances compared with native drug are P < 0.05.

Abbreviations: AUC_0–∞, area under the concentration–time curve from zero to infinity; C_max, maximal PZQ concentration in plasma; MRT, mean residence time; PZQ, praziquantel; PZQ-HCO-SLN, praziquantel-loaded hydrogenated castor oil solid lipid nanoparticle suspension; SD, standard deviation; SLN, solid lipid nanoparticle; t_½(ab), absorption half-life; t_½(d), distribution half life; t_½(el), elimination half-life; t_max, time to reach C_max.